We're all in this
October 13th is National Metastatic Breast Cancer Awareness Day. MacroGenics proudly supports National Breast Cancer Awareness Month.Continue To Site
Educational organizations supporting the HER2+ mBC community
Together, we continue the fight
Connect your patients with these organizations that provide vital support to the metastatic breast cancer (mBC) community. Each site offers different types of helpful information.
Click or tap to learn more about each organization.
Tigerlily Foundation’s mission is to educate, advocate for, empower, and support young women–before, during, and after breast cancer; and our vision is to end disparities of age, stage, and color.
Unite For HER
Unite for HER’s mission is to enrich the health and well-being of those diagnosed with breast and ovarian cancer–for life, by funding and delivering integrative therapies.
The Metastatic Breast Cancer Alliance works to unify the efforts of our members to improve the lives of, and outcomes for, those living with metastatic breast cancer and their families through increasing awareness and education about the disease, and progressing research focused on extending life, enhancing quality of life and ultimately... to cure.
Living Beyond Breast Cancer
Living Beyond Breast Cancer is a national nonprofit organization that fulfills the mission of providing trusted information and a community of support through on-demand, emotional, practical, and evidence-based content that is meaningful to those newly diagnosed, in treatment, post-treatment, and living with metastatic disease.
Young Survival Coalition
YSC is an international organization dedicated to strengthening the community, addressing the unique needs, and improving the quality of life for young adults diagnosed with breast cancer age 40 and under.
Breast Cancer Trials
BreastCancerTrials.org is a nonprofit, easy-to-use clinical trial matching service that helps people with breast cancer learn about and find trials personalized to their situation. It is a program of Quantum Leap Healthcare Collaborative.
CancerCare is the leading national nonprofit organization offering free, professional support services to anyone affected by cancer—including case management, counseling, support groups, educational resources, financial assistance, and more.
The list of independent organizations are not owned or controlled by MacroGenics which makes no representations about the services and information they may offer. Their inclusion on this website is not intended as an endorsement of the organization of the services offered, nor is it an indication of the organization’s endorsement of MARGENZA.
Be in the know
Register for the latest information and updates about MARGENZA
IMPORTANT SAFETY INFORMATION
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
- Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.
- Embryo-Fetal Toxicity: Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.
WARNINGS & PRECAUTIONS:
Left Ventricular Dysfunction
- Left ventricular cardiac dysfunction can occur with MARGENZA.
- In SOPHIA, left ventricular dysfunction occurred in 1.9% of patients treated with MARGENZA.
- MARGENZA has not been studied in patients with a pretreatment LVEF value of <50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.
- Withhold MARGENZA for ≥16% absolute decrease in LVEF from pretreatment values or LVEF below institutional limits of normal (or 50% if no limits available) and ≥10% absolute decrease in LVEF from pretreatment values.
- Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.
- Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.
- Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.
- Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
- Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.
- Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.
- Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA.
Infusion-Related Reactions (IRRs)
- MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.
- In SOPHIA, IRRs were reported by 13% of patients on MARGENZA plus chemotherapy. Most of the IRRs occur during Cycle 1. Grade 3 IRRs were reported in 1.5% of MARGENZA-treated patients.
- Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
- In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.
- Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.
MOST COMMON ADVERSE REACTIONS:
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.